Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2

NCT00000330•University of Colorado, Denver

Summary

The purpose of this study is to assess the abuse liability and reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in heroin-dependent volunteers

Detailed Description

not available at this time

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Individuals must be at least 18 yrs of age, currently opioid dependent and must not be seeking treatment. Co-morbid substance abuse or dependence disorders may also be present. Individuals must be healthy despite drug dependency and have a history of IV opioid use.

Exclusion Criteria

•Individuals with evidence of an active Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.

Locations (1)

University of Colorado Health Sciences Center

Denver, Colorado, United States

Key Dates

Start Date

October 1, 1999

Primary Completion Date

November 1, 1999

Completion Date

November 1, 1999

Last Updated

May 4, 2017

Conditions

Heroin DependenceOpioid-Related Disorders

Interventions

Opioid-Related Disorders

DRUG

Tau PET Imaging in Opioid Use Disorder

NCT05651516

Opioid-Related Disorders

View study

ACTIVE_NOT_RECRUITINGNA

Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing

NCT05505227

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 4, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5

Inclusion Criteria

Exclusion Criteria

Tau PET Imaging in Opioid Use Disorder

Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing

Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk

Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder

Erector Spinae Plane Block Versus Serratus Anterior Plane Block

Social Work Assistance and Stipends for Housing (SASH)